{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Investigators intended to report median time and its 95% confidence interval estimate using the Kaplan-Meier method, for 20 participants. Progressive disease (PD) defined according to the modified 2007 International Working Group (IWG) response criteria for non-Hodgkin lymphomas (NHL).","groups":[{"description":"Brentuximab vedotin will be given intravenously with a dose of 1.8 mg/kg every 21 days, over 30 minutes for 16 cycles in the clinic.","id":"OG000","title":"Brentuximab Vedotin Treatment"}],"paramType":"NUMBER","populationDescription":"All participants.","reportingStatus":"POSTED","timeFrame":"Up to 24 months post treatment","title":"Time to Disease Progression (TTP)","type":"SECONDARY","unitOfMeasure":"months"}